GI Symptoms Persist in Most Female Colorectal Cancer Survivors
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
WEDNESDAY, Aug. 9, 2023 -- Female colorectal cancer (CRC) survivors experience a high burden of gastrointestinal (GI) symptoms, according to a study recently published in PLOS ONE.
Claire J. Han, from The Ohio State University in Columbus, and colleagues used data from the Women’s Health Initiative Life and Longevity After Cancer study to characterize persistent GI symptoms after cancer treatments among 413 female CRC survivors.
The researchers found that during a mean 8.1 years since diagnosis, 81 percent of CRC survivors experienced persistent GI symptoms, including most commonly bloating/gas (54.2 percent), followed by constipation (44.1 percent), diarrhea (33.4 percent), and abdominal/pelvic pain (28.6 percent). Time since cancer diagnosis (less than five years), advanced cancer stage, high psychological distress, poor dietary habits, and low physical activity were significant risk factors for GI symptoms. For long-term GI symptoms, fatigue and sleep disturbance were the most significant risk factors (β = 0.21 and β = 0.20, respectively). There were positive associations observed between high severity of GI symptoms and poor quality of life, increased daily life interferences (social and physical functions), and low body image satisfaction.
"GI symptoms among survivors have been underinvestigated in the past, but we found that they are very prevalent even up to 25 years after diagnosis, suggesting it's very important to consider GI symptom management as part of their survivorship care," Han said in a statement.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2023
Read this next
Neoadjuvant Nivolumab, Ipilimumab Safe for dMMR Colon Cancer
WEDNESDAY, June 5, 2024 -- Neoadjuvant nivolumab plus ipilimumab has an acceptable safety profile in patients with locally advanced mismatch repair-deficient (dMMR) colon cancer...
Lowering FIT Positivity Thresholds Improves Sensitivity, Specificity
WEDNESDAY, June 5, 2024 -- Lowering the fecal immunochemical test (FIT) positive threshold yields levels of sensitivity and specificity that are comparable to those reported for...
Digestive Disease Week, May 18-21
Digestive Disease Week, the annual meeting sponsored by the American Association for the Study of Liver Diseases, American Gastroenterological Association, American Society for...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.